Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 37.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 240,768 shares of the biopharmaceutical company's stock after selling 141,476 shares during the quarter. Dimensional Fund Advisors LP owned 0.46% of Emergent BioSolutions worth $1,642,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of EBS. American Century Companies Inc. boosted its stake in shares of Emergent BioSolutions by 240.9% during the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company's stock valued at $6,015,000 after buying an additional 623,201 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company's stock valued at $8,631,000 after buying an additional 436,911 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company's stock valued at $1,864,000 after buying an additional 253,960 shares during the last quarter. Cetera Advisors LLC purchased a new position in shares of Emergent BioSolutions during the 1st quarter valued at approximately $428,000. Finally, Headlands Technologies LLC purchased a new position in shares of Emergent BioSolutions during the 2nd quarter valued at approximately $969,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent BioSolutions Stock Performance

EBS traded up $0.30 during trading hours on Friday, hitting $8.75. 1,272,170 shares of the stock were exchanged, compared to its average volume of 3,610,860. The stock has a 50-day simple moving average of $8.20 and a 200-day simple moving average of $6.77. Emergent BioSolutions Inc. has a 12 month low of $1.42 and a 12 month high of $15.10. The stock has a market cap of $458.52 million, a price-to-earnings ratio of -0.79 and a beta of 1.59. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.06 and a quick ratio of 0.54.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The firm had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same quarter last year, the business earned ($1.06) earnings per share. Analysts anticipate that Emergent BioSolutions Inc. will post -1.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on EBS shares. Benchmark reiterated a "buy" rating and set a $8.00 target price on shares of Emergent BioSolutions in a research note on Friday, August 16th. Rodman & Renshaw reiterated a "buy" rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.